Regeneron Pharmaceuticals, Inc.
Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
Last updated:
Abstract:
The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.
Status:
Grant
Type:
Utility
Filling date:
18 Aug 2020
Issue date:
31 Aug 2021